Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Rheumatoid arthritis

Osteopontin blockade unlikely to provide clinical benefit

Nature Reviews Rheumatology volume 7, page 621 (2011)Cite this article

Subjects

A proof-of-concept study has suggested that blockade of osteopontin (an immunomodulatory extracellular matrix protein) with the monoclonal antibody ASK8007 is well tolerated but is unlikely to provide clinical improvement in patients with rheumatoid arthritis (RA). The change in 28-joint disease activity scores after 43 days of treatment did not differ between patients receiving ASK8007 and those receiving placebo.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Boumans, M. J. H. et al. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2011-200298

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Osteopontin blockade unlikely to provide clinical benefit. Nat Rev Rheumatol 7, 621 (2011). https://doi.org/10.1038/nrrheum.2011.159

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrrheum.2011.159

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing